Avantogen Oncology, Inc. Stock price

Equities

AVTO

US05350Y1001

Biotechnology & Medical Research

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Avantogen Oncology, Inc. +11.11% -.--%
Sales 2005 - Sales 2006 - Capitalization 15.34M
Net income 2005 -5M Net income 2006 -5M EV / Sales 2005 -
Net Debt 2005 4.35M Net Debt 2006 841K EV / Sales 2006 -
P/E ratio 2005
-6.46 x
P/E ratio 2006
-2.13 x
Employees -
Yield 2005 *
-
Yield 2006
-
Free-Float 98.95%
More Fundamentals * Assessed data
Dynamic Chart
Avantogen Oncology, Inc., formerly known as Innovate Oncology, Inc., acquires, develops and seeks to commercialize compounds to treat various types of cancer. Prior to the May 26, 2006, Acquisition, the Company had been pursuing financing for a portfolio of products. The Company focused its resources on three particular product candidates: Chemo-resistance Inhibitor (RP101), Capridine beta and oral paclitaxel. In November 2006, after further evaluation of its existing pipeline, the Company decided to terminate its license agreement for oral paclitaxel. In connection with the May 26, 2006, Acquisition, the Company changed its name to Avantogen Oncology, Inc. from Innovate Oncology, Inc. (Innovate). In November 6, 2006, the Company, Gardant Pharnaceuticals, Inc. (Gardant) and Supratek Pharma, Inc. (SPI) entered into a termination of agreement and releases.
More about the company
  1. Stock
  2. Equities
  3. Stock Avantogen Oncology, Inc. - OTC Markets